JPRN-UMIN000039045已完成1 期
Phase 1 multi-center study of safety and feasibility of chemoradiotherapy using oxydol for cervical cancer - Pilot study of chemoradiotherapy using oxydol for cervical cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 90years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •less than 20 years old having distant metastasis
研究者
相似试验
招募中
1 期
Peptide-coupled Red Blood Cells for the Treatment of Multiple SclerosisRelapsing Remitting Multiple Sclerosis (RRMS)MedDRA version: 21.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2022-000801-28-ITCellerys AG142
招募中
1 期
Peptide-coupled Red Blood Cells for the Treatment of Multiple SclerosisEUCTR2022-000801-28-DECellerys AG142
招募中
1 期
Peptide-coupled Red Blood Cells for the Treatment of Multiple SclerosisEUCTR2022-000801-28-CZCellerys AG142
进行中（未招募）
1 期
APL-101 is a novel small molecule agent that is a kinase inhibitor”, which binds to the c-Met protein and disrupts the c-Met pathway that should cause cell death in tumor cells overexpressing c-Met protein.The c-Met is a protein that is frequently changed in cancers. Cancer cells often use c-Met activation to stimulate cell growth and escape therapies; therefore, the c-Met pathway is considered to be an important target for cancer therapies.on-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-001757-54-ITApollomics Inc.201
进行中（未招募）
1 期
Clinical trial to evaluate safety and effectiveness of APL-101 for the treatment MET expressing solid tumors, including Non-Small Cell Lung Cancer, Central nervous system tumors and to find the best doseon-Small Cell Lung Cancer (NSCLC) harboring (mesenchymal-epithelial transition) MET Exon 14 skipping mutationsNSCLC harboring MET amplificationPan-cancers (solid tumors) harboring MET amplificationPan cancers (solid tumors) harboring MET fusionPrimary central nervous system (CNS) tumors harboring MET alterationsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10007958Term: Central nervous system neoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-001757-54-FIApollomics, Inc.497